FDA approves inotuzumab ozogamicin for relapsed or refractory B-cell precursor ALL

28th August 2017 Uncategorised 0

European Society for Medical Oncology News

More: FDA approves inotuzumab ozogamicin for relapsed or refractory B-cell precursor ALL
Source: MDlinx